Uptake of Gilead's Yeztugo will be swift, analyst says after discussion with HIV doc
25th June 2025 Uncategorised 0What kind of uptake can Gilead expect for its long-acting HIV prophylactic injection Yeztugo, which was approved last week by the FDA? A HIV physician, who shared her views with analysts from Mizuho Securities, expects that a “majority” of her
read more

